| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8633164 | Metabolism | 2018 | 38 Pages |
Abstract
A schematic representation showing immunomodulatory therapy to treat NASH: Livers with NASH have dysregulation in β-oxidation and lipid homeostasis, and as a result lipid get accumulated in hepatocytes, which leads to hepatocyte death and inflammation. DCs recruited to NASH livers are proinflammatory with higher JNK-MAPK activation. Targeting these proinflammatory DCs with immunomodulatory liposomes induce alternative/tolerogenic phenotype and improves NASH.340
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Muralidhara Rao Maradana, Suman Kumar Yekollu, Bijun Zeng, Jonathan Ellis, Andrew Clouston, Gregory Miller, Meghna Talekar, Zaied Ahmed Bhuyan, Sachin Mahadevaiah, Elizabeth E. Powell, Katharine M. Irvine, Ranjeny Thomas, Brendan John O'Sullivan,